Sign in
4

Changes in Ownership

Kiniksa Pharmaceuticals International, plc Filed Acc 0001415889-24-028431

CHIEF FINANCIAL OFFICER sold 15,116 shares at an average $21.37 ($323,009)

  • CHIEF FINANCIAL OFFICER acquired 15,116 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Ragosa Mark CHIEF FINANCIAL OFFICER 2024-12-03 Option exercise 10b5-1 +8,969 $10.76 $96,506 31,927 D
Ragosa Mark CHIEF FINANCIAL OFFICER 2024-12-03 Sale 10b5-1 −8,969 $21.45 $192,385 22,958 D
Ragosa Mark CHIEF FINANCIAL OFFICER 2024-12-04 Option exercise 10b5-1 +5,024 $10.76 $54,058 27,982 D
Ragosa Mark CHIEF FINANCIAL OFFICER 2024-12-04 Sale 10b5-1 −5,024 $21.25 $106,760 22,958 D
Ragosa Mark CHIEF FINANCIAL OFFICER 2024-12-05 Option exercise 10b5-1 +1,123 $10.76 $12,083 24,081 D
Ragosa Mark CHIEF FINANCIAL OFFICER 2024-12-05 Sale 10b5-1 −1,123 $21.25 $23,864 22,958 D
Derivatives
Ragosa Mark CHIEF FINANCIAL OFFICER 2024-12-03 Option exercise · Share Option 10b5-1 −8,969 33,081 D
Ragosa Mark CHIEF FINANCIAL OFFICER 2024-12-04 Option exercise · Share Option 10b5-1 −5,024 28,057 D
Ragosa Mark CHIEF FINANCIAL OFFICER 2024-12-05 Option exercise · Share Option 10b5-1 −1,123 26,934 D
Open-market sales · 15,116 sh · avg $21.37 · $323,009
Loading xslF345X05/form4-12062024_121225.xml…